Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Home Clinical News
MHRA 📅 20 Feb 2024 ⏱ 1 min read

Pseudoephedrine: very rare risk of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS)

Source Update

There have been very rare reports of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS) with pseudoephedrine. This content is

Use the original MHRA report for the full story and treat this page as a linked clinical update rather than a republished article.

Why this is a brief, not a republished article

ClinicaliQ summarises and contextualises external updates for clinical awareness, then links to the original publisher for the full article and most current context.

Source
MHRA
Read Full Article ↗

More Clinical News

BBC Health · 11 Sep 2026
Running costs of vaccine damage scheme more than double amount paid to victims
BBC Health · 11 Sep 2026
Assisted dying: How laws differ around the world
BBC Health · 11 Sep 2026
‘Game-changing’ suicide prevention charity expands
BBC Health · 10 Sep 2026
Does your partner’s snoring keep you up? It could be impacting your health